Cambridge, Mass. — Anumana, an AI-driven health technology company specializing in cardiovascular diagnostics, announced an expansion of its ECG-AI™ platform to encompass the full continuum of cardiac care, including perioperative and acute care settings. This move marks a significant broadening of Anumana’s focus, which had previously centered on diagnostic solutions.
The expansion comes as part of Anumana’s Series C financing round, which includes a new investment from Boston Scientific Corporation. The additional funding will accelerate the development of Anumana’s multimodal generative AI platform and Software as a Medical Device (SaMD), further cementing the company’s position in AI-powered cardiovascular diagnostics.
The capital infusion will help advance Anumana’s industry-leading ECG-AI algorithms toward key regulatory approvals and commercial adoption, particularly within outpatient and primary care environments. The company is also focused on generating real-world clinical evidence demonstrating how its ECG-AI technology can support earlier detection and intervention in preventive cardiology.
As Anumana moves into the perioperative cardiac care space, it is developing generative AI-based imaging and visualization technologies designed to improve the precision of complex cardiac interventions. These technologies will offer real-time imaging platforms and predictive algorithms to support structural heart procedures, interventional cardiology, and electrophysiology, including cardiac ablation and left atrial appendage closure for atrial fibrillation treatment.
Anumana’s collaboration with Boston Scientific will focus on developing AI-driven tools that integrate seamlessly into clinical workflows, providing intraoperative decision support and enhancing the effectiveness of electrophysiology procedures.
“This new investment is a strong validation of Anumana’s strategic direction and momentum,” said Maulik Nanavaty, chief executive officer of Anumana. “We’ve built a solid foundation in diagnostic cardiology AI, and we’re now extending that expertise into the perioperative setting. By applying generative AI to imaging and intraoperative support, we’re creating intuitive offerings to interpret complex data in real time and facilitate delivery of care.”
Anumana’s multimodal AI systems are powered by the nference platform, which uses deidentified longitudinal data from millions of patients to develop innovative AI solutions. These tools are designed to enable earlier diagnoses, inform treatment decisions, and improve clinical workflows, aiming to disrupt current standards of cardiovascular care and improve patient outcomes.
In addition to Boston Scientific, the Series C financing round includes participation from Anumana’s longstanding investors: Matrix Capital, Mayo Clinic, Matrix Partners, and NTTVC.
